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BACKGROUND RESULTS
Valve repair is the preferred treatment in paediatric patients with val-
vular heart disease. However, replacement is sometimes un-
avoidable.  
In young patients, the use of a mechanical prosthesis is favoured to 
avoid reoperations for premature structural degeneration of the valve.
However, mechanical valve replacement in a paediatric population is li-
mited by small cardiac dimensions and the need for lifelong oral anti-
coagulation.
Limited long-term data is available, especially regarding INR manage-
ment and valve-related events.
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METHODOLOGY
Ghent experience: January 1984 - December 2015
40 patients received a mechanical prosthesis before age 20
  5 were lost to follow-up
  28 received INR follow-up by their GP
  7 used a self-monitoring INR device
Study endpoints:
  Survival
  Valve-related events
  INR variability
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VALVULAR PATHOLOGY
Main diseased valve (to be replaced)
  Mitral 55 %
25 %
  Tricuspid 10 %
  Pulmonary 5 %
5 %
CARDIAC STATUS
82.5 %
    1 42.5 %
    > 1 40 %
DEMOGRAPHICS
Gender
    Male 60 %
    Female 40 %
Age 12 ± 2 y 
NYHA class
    I 15 %
    II 52 %
    III 23 %
    IV 10 %
PREOPERATIVE DATA
Contact: Jonas Verbeke  - University Hospital of Ghent, Belgium - jdverbek.verbeke@ugent.be
Congenital
Genetic
Rheumatic
Infectious
Etiology of valvular dysfunction
Mitral
anomaly
Aortic valve 
anomaly
TGA
TOF
Tricuspid anomaly 
(Ebstein)
Single ventricle
VSD
None
Ascending AO 
aneurysm
     Aortic 
coarctation
Other structural 
cardiac defects 
(ASD, VSD)
Down syndrome Marfan
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CONCLUSION
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Survival and type of INR follow-up
Physician
Self-monitoring (e.g. Coagucheck)
Follow-up (FU)
 Median FU-time: 12.9 ± 9.2 y  - 88 % completeness (incl. INR: 79%) 
 Cumulative FU-time: 540 patient-years
•
•
• 40% of the patients receiving a mechanical heart valve prosthesis 
during childhood experience at least one major adverse event during 
later life.
Half of these events are related to the need for anticoagulation, 
through showing a high INR variability in this young population.
Self-monitoring of INR might decrease this speciﬁc complication rate.
•
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Valve- and anticoagulation (AC)-related events and INR variability
 60% of patients remained free of any major valve-related event
 INR-variability: 29 ± 21% (self-mon.) vs 43 ± 21% (GP mon.) (p=0.05)
 High INR variability was associated with more AC-related events
 No AC-related events were seen in patients using INR self-monitoring
•
TIA
Major thrombo-
embolism 
Major bleeding Valve dysfunction
Endocarditis
< 20 %
20 - 40 %
> 40 %
•
Survival at 20 y: 76 ± 10 %
•
•
INR variability
> 40 %20 - 40 %< 20%
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AC-related events and INR variability
INR variability (overall)
Distribution of valve-related events
Patients who suﬀered from 1 or more 
AC-related event(s) during follow-up 
Patients who remained free from any 
AC-related event(s) during follow-up
